Study in Patients With Asthma

Phase 2

Completed

• Conditions: Asthma

• Registration Number: NCT00215397
• Lead Sponsor: Dey

Brief Summary

The purpose of this study is to determine which dose of the investigational drug is the most safe and effective in the treatment of asthma compared to the control drug.

Detailed Description

Not available

Study Timeline

• Primary Completion: 2003-02
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-14
• Study First Posted: 2005-09-22
• Study Completion: 2005-12
• Status Verified: 2008-02
• Last Update Submitted: 2010-11-10
• Last Update Posted: 2010-11-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

• Patients with a history of asthma

Exclusion Criteria

• Current asthma exacerbation or recent asthma exacerbation, requiring hospitalization
• History of smoking
• Debilitating systemic and/or life-threatening diseases.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
The primary outcome variable is the measure of lung function.

Secondary Outcome Measures

Name	Time	Method
Secondary outcomes include change in lung function, as well as in vital signs.
Physical exams, AE reporting, etc.

Trial Locations

Locations (1)

Research Site; 🇺🇸 Medford, Oregon, United States